





Q3 FY2018 Quarterly Results - Investor presentation 7 February 2018





THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES IN THE UNITED STATES OF AMERICA OR IN ANY OTHER JURISDICTION. IT IS PROVIDED AS INFORMATION ONLY.

This presentation is furnished only for the use of the intended recipient, and may not be relied upon for the purposes of entering into any transaction. By attending this presentation, you agree to be bound by these restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Certain information herein (including market data and statistical information) has been obtained from various sources. We do not represent that it is complete or accurate. All projections, valuations and statistical analyses are provided to assist the recipient in the evaluation of the matters described herein. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent that they are based on historical information, they should not be relied upon as an accurate prediction of future performance.

This presentation may include forward-looking statements that reflect our intentions, beliefs or current expectations. Forward-looking statements involve all matters that are not historical by using the words "may", "will", "would", "expect", "intend", "estimate", "anticipate", "believe", and similar expressions or their negatives. Such statements are made on the basis of assumptions and expectations that we currently believe are reasonable, but could prove to be wrong.

This presentation does not constitute an offer or an agreement, or a solicitation of an offer or an agreement, to enter into any transaction (including for the provision of any services) and does not constitute an offer or invitation to subscribe for or purchase any securities, and nothing contained herein shall form the basis of any contract or commitment whatsoever. Any decision to purchase securities in the context of a proposed offering, if any, should be made solely on the basis of information contained in the offering memorandum published in relation to such an offering.

The information contained herein does not constitute investment, legal, accounting, regulatory, taxation or other advice and the information does not take into account your investment objectives or legal, accounting, regulatory, taxation or financial situation or particular needs. You are solely responsible for forming your own opinions and conclusions on such matters and the market and for making your own independent assessment of the information herein. You are solely responsible for seeking independent professional advice in relation to the information and any action taken on the basis of the information. Investors and prospective investors in the securities of any issuer mentioned herein are required to make their own independent investigation and appraisal of the business and financial condition of such issuer and the nature of the securities.

This presentation includes certain financial data that are "non-IFRS financial measures". These non-IFRS financial measures do not have a standardised meaning prescribed by International Financial Reporting Standards or UK Accounting Standards and therefore may not be directly comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in accordance with International Financial Reporting Standards or UK Accounting Standards. Although we believe these non-IFRS financial measures provide useful information to users in measuring the financial performance and condition, of the business, you are cautioned not to place undue reliance on any non-IFRS financial measures included in this presentation. This presentation contains certain data and forward looking statements regarding the UK economy, the markets in which we operate and its position in the industry that were obtained from publicly available information, independent industry publications and other third party data. We have not independently verified such data and forward looking statements and cannot guarantee their accuracy or completeness.

Agenda



- New appointments Group Commercial Director
- Strategy overview
- Performance & business update
 - mydentist developments
 - Dental Directory developments
- Q3 FY2018 financial review
- Summary







New appointments






Dr Julian Perry – Group Commercial Director

- Joined IDH Group as Group Commercial Director in January 2018
- Over 30 years experience in dentistry including over 20 years in multi-site ventures
- Julian joins IDH from Oasis Dental Care, now BUPA Dental where he held numerous roles including Group Clinical Director and Director of Acquisitions
- Part of the successful turnaround and sale of Oasis
- Continues to work as a part time practicing clinician specialising in Implantology

New appointments











Strategy overview




Our strategic priorities

		Description		
1	Improve clinician and nurse resourcing and retention	Build a best-in-class recruitment team to promote a more compelling clinician proposition and fill all vacancies		
2	Evaluate the portfolio	Assess the portfolio to identify and create a plan for loss-making practices		
3	Optimise practice productivity	Increase practice productivity to drive improved UDA completion rates, and number of committed hours per dentist		
4	Buffer and mitigate short term costs	Assess and rationalise the cost base across the group		
5	Continue growth of private	Develop and roll-out an affordable private proposition across specialist treatments and Private Payment Plans		
6	Continue growth in Dental Directory	Grow the business and build a leading lab offering		
7	Maintain high clinical standards	Develop best-in-class clinical pathways and procedures to deliver consistent, high quality and ethical dental care		



Q3 FY2018
Performance & business update



Q3 FY2018 group performance





Group

- Revenue down 1.0% YoY to £147.9m
- Q3 EBITDA down £2.4m to £14.4m
- Year-to-date revenue down 0.6% to £432.2m and EBITDA down to £40.9m



mydentist

- Private revenue LFL growth of 5.6% per working day
- Divisional revenue down 1.6% due to lower UDA delivery
- Gross margin improved to 47.2%



Dental Directory

- Revenue growth of 5.0% YoY to £36.1m (before intergroup eliminations)
- Gross margins down 1.9% on Q3 FY2017

Q3 FY2018 highlights – mydentist



NHS revenue

- NHS revenue of £93.7m, down £3.2m (-3.3%) for the quarter
- As expected like-for-like UDA delivery per working day down 5.8% compared to Q3 FY2017
- In line with our strategy we see positive signs in clinician recruitment and engagement but this is not yet feeding into the financial results
- Management time focused on:
 - Increasing the number of hours dentists are available
 - Increasing the UDAs contracted per dentist
 - Managing private revenue growth to ensure patient choice while delivering the commitment to the NHS

Q3 FY2018 highlights – mydentist



Private revenue

- Private revenue for Q3 was £25.5m, an increase of 4.9% on last year
- Like-for-like private growth for the quarter was 5.6%; adjusted for the number of working days YTD, the increase was 7.3%
- Strong growth in general private (+13.9% LFL over two years) reflects choice given to patients
- Additional services such as hygiene (+16.4% LFL over two years) provides additional options to patients
- In line with our strategy we are progressing with the roll-out of our first 8 specialist implant centres which will open at the start of the next financial year

Q3 FY2018 highlights – mydentist



Resourcing & on-boarding

- The full resourcing and on-boarding team are now in place
- Execution of the strategic plan to build up the pipeline of new dentists and make on-boarding as efficient as possible remains a key management focus – the pipeline is at record levels
- Additional resourcing days held in Manchester and London after regional days held across the country – Bristol, Manchester, Wembley, York and Sheffield
- 54 offers from these events
- Overseas days held in Greece, Romania, Bulgaria, Poland, Spain and Portugal
- An additional net 165 clinicians engaged year to date
- Clinician churn remains low and under 10%

Q3 FY2018 highlights – Dental Directory {idh}group



- Total revenue excluding sales to mydentist up 1.8% to £28.6m, but up 7.3% YTD.
- Growth in revenue driven by the High Street up 7.6% YTD although trading conditions were tough in December.
- Fluctuations in the currency markets have impacted purchase and stock prices year-on-year although gross margin impact has been mitigated over time by working with suppliers and optimising pricing.
- BF Mulholland acquisition made in October with a pro-forma EBITDA increase of £0.6m.





Q3 FY2018 Financial highlights



- Group revenue down 1.0% year-on-year to £147.9m
- LFL mydentist private revenue up 5.6%
- Private revenue now 17.3% of total revenue (Q3 FY2017: 16.3%)
- NHS revenue 63.4% of total (Q3 FY2017: 64.9%)
- Dental Directory revenue 19.3% of total (Q3 FY2017: 18.8%)
- As expected EBITDA down £2.4m on Q3 FY2017 to £14.4m
- LTM EBITDA £57.9m

Financial results for Q3 FY2018 Income statement




	Q3 FY2018 £m	% of revenue	Q3 FY2017 £m	% of revenue	% change
Revenue	147.9		149.4		(1.0)%
Gross profit	62.5	42.3%	65.2	43.7%	(4.1)%
Overheads*	(48.6)	32.9%	(48.9)	32.8%	0.6%
Other operating income	0.5	0.3%	0.5	0.4%	(7.5)%
EBITDA	14.4	9.7%	16.8	11.3%	(14.4)%

^{*} Administrative expenses plus distribution costs before depreciation, amortisation, impairment and other non-underlying items

Financial results for Q3 FY2018


Group revenue bridge





Financial results for Q3 FY2018 Group EBITDA bridge





Financial results for Q3 FY2018

Acquisitions & Disposals



- Total of 654 practices at 31 December 2017 (677 at 31 December 2016)
- In line with our strategy the portfolio review has identified a number of practices which are no longer sustainable
 - 4 practices closed in Q3 (YTD 12 practices)
 - 3 practices disposed (YTD 7 practices)
 - An additional 12 practices reclassified as "held for sale" on the balance sheet and the excess of book value compared to estimated realisable value written off during Q3
 - 26 practices now classified as held for sale
- Limited further disposals and closures being considered as highlighted at the year-end and as part of the strategic review
- No current plans for any further acquisitions

Financial results for Q3 FY2018 Cash flow statement



£m	Q3 FY2018	Q3 FY2017
Cash generated from operations	9.7	7.7
Net capital expenditure	(3.6)	(3.8)
Corporation tax	-	-
Cash flow before acquisitions and debt service	6.1	3.9
Interest	(5.6)	(6.8)
Cash flow before acquisitions and financing	0.5	(2.9)
Acquisitions*	(4.5)	(3.5)
Debt issue costs	-	(1.7)
Financing	5.0	-
Net cash flow	1.0	(8.1)
Opening cash	15.1	18.0
Closing cash	16.1	9.9
Net debt	531.0	529.7

^{*}Excluding fees

Financial results for Q3 FY2018 Cash conversion



£m	Q3 FY2018	Q3 FY2017
Operating cash flow	9.7	7.7
Exceptionals	0.9	1.6
Acquisition fees	0.3	0.2
Working capital adjustments	-	-
Adjusted operating cash flow	10.9	9.5
Maintenance capital expenditure	(3.8)	(3.2)
Adjustments	-	-
Adjusted cash flow	7.1	6.3
EBITDA	14.4	16.8
Adjusted cash conversion %	49.4%	37.6%

Summary



- New high quality leadership team in place
- Ambitious agenda to meet our strategic goals
- Management focus is on the key areas to deliver the operational plans that underpin the strategy
- Good progress in:
 - Resourcing
 - Portfolio review
 - Private & specialist



Contact details:

Further questions can be addressed to:

- Email: investorrelations@mydentist.co.uk

- Telephone: 01204 799651

Investor information is available from our dedicated investor website:

www.mydentist.co.uk/about-us/investors

